LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis

Abstract Several studies in humans and animals suggest that LDL particle core enrichment in cholesteryl oleate (CO) is associated with increased atherosclerosis. Diet enrichment with MUFAs enhances LDL CO content. Stereoyl O-acyltransferase 2 (SOAT2) is the enzyme that catalyzes the synthesis of much of the CO found in LDL, and gene deletion of SOAT2 minimizes CO in LDL and protects against atherosclerosis. The purpose of this study was to test the hypothesis that the increased atherosclerosis associated with LDL core enrichment in CO results from an increased affinity of the LDL particle for arterial proteoglycans. ApoB-100-only Ldlr−/− mice with and without Soat2 gene deletions were fed diets enriched in either cis-MUFA or n-3 PUFA, and LDL particles were isolated. LDL:proteoglycan binding was measured using surface plasmon resonance. Particles with higher CO content consistently bound with higher affinity to human biglycan and the amount of binding was shown to be proportional to the extent of atherosclerosis of the LDL donor mice. The data strongly support the thesis that athero-sclerosis is induced through enhanced proteoglycan binding of LDL resulting from LDL core CO enrichment.—Melchior, J. T., J. K. Sawyer, K. L. Kelley, R. Shah, M. D. Wilson, R. R. Hantgan, and L. L. Rudel. LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis. J. Lipid Res. 2013. 54: 2495–2503.

Supplementary key words lipoprotein • fatty acid • glycosaminoglycan • cholesterol

Atherosclerosis is the disease process in the artery wall leading to clinical complications of coronary heart disease, a disease that has cost more lives in the United States over the past century than the next four diseases combined (1). The subendothelial retention and accumulation of LDL in the artery wall is now recognized as an initiating event in the pathophysiology of atherosclerosis (2). After LDL particles enter the intima of the artery wall, they can interact with proteoglycans, which are structural proteins residing in the extracellular matrix that consist of one or more glycosaminoglycan (GAG) side-chains attached to core proteins. The LDL-proteoglycan complex is generally regarded as an electrostatic interaction (3). The sulfation pattern of the acidic sugar groups that form the GAG chains on the proteoglycans results in an overall negative charge that can interact with clusters of positively charged amino acid residues on apoB-100, the primary apolipoprotein present on the LDL particle (4). A proteoglycan frequently deposited in atherosclerotic plaques of humans (5, 6) and mice is biglycan (BGN) (7).

While plasma LDL cholesterol concentrations are predictive of the extent of atherosclerosis, LDL particles are heterogeneous in size and composition, and this heterogeneity may provide additional useful information about the role of LDL in atherosclerosis. For instance, studies have shown that diet-induced alterations in the FA composition of LDL core cholesteryl esters (CEs) can influence the atherogenic potential of LDL particles (8–11). In nonhuman primates, consumption of dietary MUFAs resulted in LDL particles containing a CE core enriched in cholesteryl oleate (CO), which were positively associated with coronary artery atherosclerosis (r = 0.8) (10, 11). Importantly, a similar diet-related shift in the FA composition of LDL has been observed in humans in which consumption of oleate-enriched diets resulted in elevations in the percentage of CO in the LDL CE (12). Additionally, the large Atherosclerosis Risk in Communities Study revealed a

Abbreviations: BGN, biglycan; CE, cholesteryl ester; CO, cholesteryl oleate; CS, chondroitin sulfate; DLS, dynamic light scattering; FC, free cholesterol; GAG, glycosaminoglycan; PL, phospholipid; RT, room temperature; RU, response unit; SOAT2, stereoyl O-acyltransferase 2; SPR, surface plasmon resonance; TC, total cholesterol; TG, triglyceride; TPC, total plasma cholesterol; UC, ultracentrifugation.

To whom correspondence should be addressed.

e-mail: lrudel@wakehealth.edu

The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of four figures.

John T. Melchior,* Janet K. Sawyer,* Kathryn L. Kelley,* Ramesh Shah,* Martha D. Wilson,* Roy R. Hantgan,† and Lawrence L. Rudel*†‡

Department of Pathology, Section of Lipid Sciences,* and Department of Biochemistry, † Wake Forest University School of Medicine, Winston Salem, NC

Published, JLR Papers in Press, June 26, 2013
DOI 10.1194/jlr.M039644

Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at http://www.jlr.org

Journal of Lipid Research Volume 54, 2013 2495
significant positive association between the percentage of plasma CE as CO and carotid artery intima-media thickness in patients with preclinical atherosclerosis (13).

Steroyl O-acyltransferase 2 (SOAT2) is a membrane-bound enzyme localized to the endoplasmic reticulum in hepatocytes and enterocytes that is at least partially responsible for the incorporation of CO into apoB-containing lipoproteins (14). Gene deletion of Soat2 in mouse models has been shown to protect against LDL CO enrichment and the development of atherosclerosis, supporting the claim that inhibition of CO production is a viable therapeutic target in the treatment of disease (8, 15). Although evidence consistently implicates CO as an important component in the development of atherosclerosis, the mechanism by which it promotes accelerated disease development has remained elusive. The primary goal of this study was to establish whether LDL particle core enrichment with CO enhances interactions between the LDL particle and resident arterial proteoglycans, which could accelerate the development of atherosclerosis via increased LDL particle retention. To accomplish this goal, we developed a novel assay using surface plasmon resonance (SPR) technology to quantify the interaction of LDL particles with arterial proteoglycans.

METHODS

Mice and diets
The apoB-100-only Ldlr−/− mouse (75% C57Bl/6, 25% 129Sv) (16) used in this study was a gift from Dr. Steven Young. Two mouse lines on the apoB-100-only LDL receptor-deficient background were compared for these studies; apoB-100-only Ldlr−/−, Soat2−/− and apoB-100-only Ldlr−/−, Soat2−/−, which were generated as previously described (8). Littermate controls were used to account for genetic heterogeneity. At about 6 weeks of age, mice were switched from a rodent chow diet to one of two semipurified diets consisting of 10% energy as fat with 0.02% cholesterol (wet weight) enriched in either long-chain n-3 PUFAs (20% of total FAs). Details of the dietary ingredients and FA compositions have previously been described (8). All experimental animals were euthanized between 10 and 16 weeks of diet treatment. Various endpoints were assessed during this period at the time points indicated. While the plasma cholesterol concentrations and atherosclerosis extent both tend to rise with time of diet exposure, the mice used for LDL binding studies were also evaluated for atherosclerosis extent so that direct comparisons could be made. Mice were maintained in an American Association for Accreditation of Laboratory Animal Care-approved pathogen-free animal facility, and the institutional Animal Care and Use Committee at Wake Forest University Health Sciences approved all experimental protocols.

Plasma lipid and lipoprotein distribution
Blood was taken from each mouse at the terminal time point via heart puncture and transferred to tubes containing 10 μl of protease inhibitor cocktail (Sigma P2714) in 5% Azide and 5% EDTA, and lipids and lipoproteins were measured. Plasma was separated from red blood cells by centrifugation at 7,500 g for 15 min at 4°C. Total plasma cholesterol (TPC) concentrations were determined by enzymatic assay as described previously (17, 18). Cholesterol distribution among lipoprotein classes was determined after an aliquot of whole plasma was fractionated by gel filtration chromatography using a Superose-6 10/30 column (GE Healthcare) run at a flow rate of 0.5 ml/min as previously described (15).

LDL isolation
It has previously been reported that isolation of LDL particles by density gradient ultracentrifugation (UC) can dissociate minor apolipoproteins from the particle surface, which could play a role in binding to arterial proteoglycans (19). Thus, a majority of the binding experiments used LDL particles isolated chromatographically as previously described (8).

A Superose 6 10/30 column was equilibrated with sample buffer (100 mM HEPES, 20 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, pH 7.4) containing 50 μl of protease inhibitor (Sigma P8340) per liter of buffer. For LDL isolation, 350 μl of plasma diluted 1:1 with PBS was injected onto the column, and fractions were eluted at a flow rate of 0.4 ml/min. For LDL binding assays, a narrow center of the peak window (23–28 min) was collected and pooled. For LDL compositional analysis, the entire window corresponding to the LDL peak was collected and pooled. After collection, LDLs were maintained at 4°C until analysis.

For comparison, subsets of LDL were also isolated between densities of 1.019 and 1.063 g/ml by ultracentrifugation from pooled plasma (n = 3 mice per group) of all four experimental groups, as previously described (20). All centrifugation steps were performed at room temperature (RT) and the floated LDL was stored at either RT or 4°C until experimental use.

Recombinant BGN isolation
Recombinant BGN was produced using a stable transfected 293-EBNA cell line at LifeCell Corporation. The cell line was created by transferring a BGN polyhistidine fusion construct, originally created for expression using a vaccinia virus expression system (21), into the pCEP4 (Invitrogen Corporation; Carlsbad, CA) expression vector. The resulting plasmid was transfected into 293-EBNA cells and stable-expressing cells selected by culturing in the presence of hygromycin B. Following amplification, cells were seeded into a Celligen Plus bioreactor (New Brunswick Scientific; Edison, NJ) containing 100 g Fibra-Cel disks and grown to saturation. Protein production was initiated by replacing the culture media with serum-free DMEM. Conditioned media was collected every 48 h, with fresh media added back to the bioreactor. Following concentration of the conditioned media using a Pellicon 2 tangential flow system (Millipore Corporation; Bedford, MA), recombinant biglycan was purified using nickel chelating chromatography and elution with a gradient of 0–250 mM imidazole in 20 mM Tris-HCl, 500 mM NaCl, 0.2% CHAPS, pH 8.0. Protein core that had not been well glycosylated was subsequently separated from proteoglycan following anion exchange chromatography on Q-Sepharose and elution with a linear gradient of 0.15–2 M NaCl in PBS, 0.2% CHAPS. Using Coomassie staining, there was no detectable unglycosylated core protein remaining in the proteoglycan preparation as seen after polyacrylamide gel electrophoresis.

LDL-BGN interaction
A Biacore T100 SPR platform (22, 23) was used to quantify the interaction of LDL with immobilized BGN. In the first step, the dextran surfaces of a CM5 biosensor chip (Biacore, Inc.; Piscataway, NJ), for both reference and sample channels, were activated for amine coupling (22). Following surface activation, an antigen affinity-purified polyclonal goat IgG, specific to BGN core protein (R and D Systems; AF2667), was covalently coupled to the dextran surface of the chip through its lysine residues, reproducibly yielding a sparse IgG monolayer in both channels.
GAG chains to enable LDL binding. An average RU loss of only 3.6 ± 0.9% over 1,700 s. Immunocap-tion of the mAb sample channel surface (1,239 ± 18 RU, n = 30) in sample buffer at a flow rate of 30 s. Residual RU after each wash = 34 µg/ml protein at a flow rate of 20 µl/min for 180 s followed by a 300 s stabilization period to achieve ~10% saturation of the mAb sample channel surface (1,239 ± 18 RU, n = 30) (see supplementary Fig. IA). BGN capture was quite stable, with an average RU loss of only 3.6 ± 0.9% over 1,700 s. Immunocapture of BGN through its protein core increases the exposure of its GAG chains to enable LDL binding.

After BGN immobilization, various LDL particle sizes were delivered in sample buffer at a flow rate of 30 µl/min for 700 s (binding) to both the reference (mAb only) and sample channels (mAb-BGN), followed by sample buffer at the same rate for 1,000 s (disso-caction) (see supplementary Fig. IB). After the binding interaction, 3 M sodium thiocyanate was delivered at a flow rate of 30 µl/min to remove the LDL:BGN complex, yielding a fresh mAb surface (Res-idual RU after each wash = −1 ± 6, n = 6). The biosensor surface was then equilibrated for 300 s with sample buffer prior to the next cycle of BGN capture, LDL binding, and regeneration.

A majority of the binding assays were performed using LDL isolated from whole plasma by HPLC. LDLs were maintained at 10°C in the SPR sample compartment, and data were collected at 25°C. Importantly, binding experiments were performed with fresh LDL (within 24 h of preparation of plasma) to avoid any potential loss in binding signal over time (see supplementary Fig. II). Binding kinetics and concentration curves (0–40 µg/ml LDL cholesterol) for LDL isolated from pooled plasma samples (n = 3 mice/pool) can be found in Fig. 2. All remaining binding experiments were performed on LDL from individual mice at a concentration of 30 µg/ml of LDL cholesterol.

To ensure that CE composition-related differences in binding were not influenced by extraneous proteins coeluting with the LDL particles isolated by HPLC, comparator binding assays were also performed on LDL isolated by UC. Because particle storage temperature and binding temperature also could affect LDL binding, particles isolated and stored at RT were maintained at 25°C in the sample compartment, and data were collected at either 37°C or 25°C (see supplementary Fig. IIIA, B). Particles were also stored at 4°C and maintained in the sample compartment at 10°C, and binding data were collected at 25°C (see supplementary Fig. III for comparison).

**LDL particle composition**

LDL particle size was determined using size exclusion chromatography with concomitant dynamic light scattering (DLS). After LDL particle isolation, 150 µl of the LDL was injected onto the Superose 6 column and eluted with sample buffer at a flow rate of 0.4 ml/min. Detection was performed at a wavelength of 661 nm by refractive index detector model Optilab REX (Wyatt Technology) and MALSS detector model DAWN HELEOS II (Wyatt Technology). Signals from the detectors were processed using ASTRA software, version 6.0.1.10 (Wyatt Technology), and the hydrodynamic radius was evaluated at the peak of the size distribution curve, generated as a function of particle retention time.

Chemical compositions of the isolated LDLs were determined with enzymatic assays for total cholesterol (TC), free cholesterol (FC), triglyceride (TG), and phospholipid (PL) (TC by Pointe Scientific, Inc.; FC, TG, and PL by Wako Chemicals USA). Total CE mass was calculated for individual LDLs by subtracting the FC from the TC and then multiplying by 1.67 to account for the mass of the acyl chain. LDL CEs were detected and quantified by mass spectrometry as previously described (28). For CE composition analyses, 10 µl of the LDL isolated by HPLC was stored at −80°C under argon to prevent oxidation prior to analysis. At the time of analysis, samples were thawed and diluted in 1 ml of methanol solution containing 500 µg/µl of 17:0 CE as the internal standard and 1 ng/µl of sodium formate. CEs were measured using a Quattro II mass spectrometer equipped with a Z-spray interface (capillary voltage = 3.2 kV; cone voltage = 50 V; source temperature = −80°C; desolvation temperature = 200°C). Samples were maintained at 15°C in a temperature-controlled Spark Holland Reliance autosampler/stacker until analysis. Twenty-five microliters of each sample was infused into the mass spectrometer at 10 µl/min. CEs were quantified in the positive-ion mode by monitoring the common neutral loss of 368.5 Da. The CE molar concentrations were calculated from individual profiles (see supplementary Fig. IV) and the internal standard. Individual CE measurements are reported as percentages of total CE mass.

Protein was measured by the method of Lowry et al. (29) on the ultracentrifuge-isolated LDL. Estimates of the protein for the column-isolated LDL were extrapolated by using the TC:PRO ratio of the centrifugally isolated LDL preparations. Data for the LDL chemical compositions are expressed as a percentage of the total lipid plus protein mass.

**Quantification of atherosclerosis**

Aortic atherosclerosis was evaluated using both en face and chemical techniques. At the time of necropsy, aortas were removed from mice and preserved in 10% neutral buffered formalin. After a minimum of 24 h fixation, all extraneous tissue and arterial branches were removed from the aorta. In a subset of three mice per experimental group, the aorta was opened longitudinally, pinned flat, and photographed with an mm marker on the photo. After the image was grabbed using Image J software, the entire surface of the aorta and each lesion area were digitized using a digitizing tablet interfaced to a computer using the mm marker as a correction factor. Lesion areas were defined as raised opaque areas on the aortic surface. The percent surface area with lesions was calculated as a simple ratio of aortic lesion area to aorta total surface area. In aortae from all animals, including those used for surface measurements, lipids were extracted in 2:1 chloroform-methanol in a test tube containing a known amount of 5α-cholestan as an internal standard. TC and FC (the latter after saponification) were determined by gas-liquid chromatography, and aortic CE concentration was calculated. The correlation between aortic CE concentrations and surface area occupied by lesion was consistently r ≈ 0.9 in this and other experiments (see supplementary Fig. V).

**Statistical analysis**

All statistical analyses were conducted using JMP Software (version 5.01.2; Cary, NC). Two-way analysis of variance was used for analyses in which two independent variables were compared, and statistical significance is indicated where observed. Relationships between binding and disease parameters were analyzed by regression analysis and least-squares best-fit regression lines; regression coefficients are included in those figures.

**RESULTS**

**Plasma and lipoprotein cholesterol**

The data shown in Fig. 1 are from mice of each diet and genotype group as measured after 11 weeks of diet.
exposure. Two-way ANOVA was used to identify statistically significant differences. In apoB-100-only Ldlr−/− mice, consumption of a diet containing n-3 PUFA limited diet-induced hypercholesterolemia compared with mice fed the cis-MUFA diet (Fig. 1A). No significant difference in TPC between Soat2+/+ versus Soat2−/− mice was seen. Cholesterol distributions among the lipoprotein classes showed that the increase in TPC levels observed in the cis-MUFA-fed mice was a result of significant elevations in cholesterol of both VLDL and LDL, with LDL comprising about 80% of the total cholesterol pool in both Soat2+/+ and Soat2−/− mice (Fig. 1B,C). No significant difference between Soat2 genotypes was seen for either VLDL or LDL cholesterol concentrations by two-way ANOVA. For HDL cholesterol, both dietary FA (P = 0.0008) and Soat2 genotype (P = 0.03) effects were found to be significant by two-way ANOVA.

**LDL composition**

Percentage compositions of LDL particles isolated by HPLC from individual mice are shown in Table 1. The primary differences in lipid components were limited to the core lipids, i.e., CE and TG. Compared with LDL of Soat2+/+ mice, LDL particles produced by the Soat2−/− mice contained lower percentages of CE and higher percentages of TG, and these differences appeared to be independent of diet. The combined proportions of surface constituents (FC, PL, plus PRO) versus core lipids (CE plus TG) were similar for all groups, and particle diameters, obtained by DLS, showed only a small range of sizes among the particles (25–26 nm). Soat2−/− mice consuming the cis-MUFA diet had slightly larger LDL particles compared with the other experimental groups.

Individual CE compositions of LDL were quantified by mass spectrometry, and percentages based on FA components are shown in Table 2. Dietary fat type and Soat2 deletion significantly altered the CE species of the LDL particle core. The rank order of monounsaturated fat content of the CE in LDLs isolated from the experimental groups was: Soat2+/+ fed the cis-MUFA (45%) > Soat2+/+ fed the n-3 PUFA (31%) > Soat2−/− fed the cis-MUFA (19%) > Soat2−/− mice fed the n-3 PUFA (11%). Soat2+/+ mice fed cis-MUFA and n-3 PUFA had CEs that consisted primarily of n-6 PUFAs (64% and 56%, respectively). In contrast, the percentage of CEs consisting of the n-6 polyunsaturated fat in Soat2+/+ mice fed cis-MUFA and n-3 PUFA were 40% and 17%, respectively. In sum, LDL cholesterol ester composition was highly sensitive to both SOAT2 status and dietary fat composition.

In summary, mice consuming the cis-MUFA diet had the highest LDL cholesterol concentrations, although no significant differences between the Soat2+/+ and Soat2−/− mice were observed. The percentage of LDL total mass that was monounsaturated CE was 19.5% in Soat2+/+ mice consuming the cis-MUFA diet and was 12.7% in Soat2+/+ mice fed the n-3 PUFA diet. In contrast, Soat2−/− mice consuming the cis-MUFA diet had 6.25% of LDL mass as monounsaturated CE, whereas Soat2−/− mice had LDL particles with only 3.85% of mass as monounsaturated CE.

**LDL binding to biglycan**

LDL binding to human BGN was measured using SPR by delivering LDL particles isolated from mice to immunocaptured human BGN, the core protein of which shares

---

**Table 1. Effect of diet and Soat2 deletion on LDL particle composition**

| Genotype | Diet     | FC      | CE      | TG      | PL      | PRO     | Diameter (nm) |
|----------|----------|---------|---------|---------|---------|---------|---------------|
| Soat2+/+ | cis MUFA | 10.8 (0.4) | 43.0 (1.0) | 1.9 (0.5) | 25.8 (2.0) | 18.6 (0.5) | 25.0 (0.3) |
| Soat2−/− | n-3 PUFA | 11.9 (0.3) | 41.6 (0.9) | 2.8 (0.8) | 23.6 (1.6) | 20.1 (0.4) | 24.0 (0.4) |
| Soat2+/+ | cis MUFA | 10.9 (0.3) | 34.1 (0.7) | 10.3 (0.5) | 21.2 (0.7) | 25.7 (0.3) | 23.9 (0.6) |
| Soat2−/− | n-3 PUFA | 11.8 (0.6) | 34.5 (1.7) | 8.7 (1.2) | 27.2 (3.3) | 17.7 (0.8) | 23.2 (0.4) |
| Two-way ANOVA | | | | | | | |
| Diet effect | | | | | | | |
| Genotype effect | ns | P < 0.0001 | P < 0.0001 | ns | ns | ns | P = 0.004 |
| Interaction effect | ns | ns | ns | ns | ns | ns | P = 0.003 |

LDL diameter was determined using DLS. All values represent the means (± SEM) for 15–17 mice for each diet/genotype group.
TABLE 2. Individual cholesteryl esters of LDL

| Genotype          | Diet   | 16:0 | 18:0 | 16:1 | 18:1 | 20:4 | 18:3 | 20:5 | 22:6 |
|-------------------|--------|------|------|------|------|------|------|------|------|
| Soat2+/+ cis-MUFA | 5.5 (0.3) | 1.2 (0.2) | 9.9 (0.4) | 35.3 (2.6) | 13.2 (0.7) | 27.1 (2.5) | 0.8 (0.1) | 1.9 (0.2) | 5.1 (0.4) |
| Soat2+/+ n-3 PUFA | 6.2 (0.3) | 1.2 (0.2) | 14.0 (0.7) | 16.5 (0.5) | 7.4 (0.4) | 10.0 (0.4) | 1.2 (0.1) | 33.6 (1.1) | 10.0 (0.5) |
| Soat2+/- cis-MUFA | 3.7 (0.5) | 0.8 (0.2) | 5.2 (0.7) | 13.2 (3.6) | 19.1 (1.2) | 44.6 (3.5) | 1.0 (0.1) | 3.5 (0.5) | 8.9 (0.7) |
| Soat2+/- n-3 PUFA | 3.4 (0.3) | 0.5 (0.1) | 5.7 (0.2) | 5.5 (0.5) | 10.7 (0.4) | 16.7 (0.6) | 1.0 (0.1) | 42.3 (1.5) | 14.2 (0.5) |

Two-way ANOVA

Diet effect ns ns ns P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 ns ns ns P < 0.0001 P < 0.0001 P < 0.0001 ns
Genotype effect ns ns ns P < 0.0001 P < 0.0001 P < 0.0001 ns ns ns ns ns ns ns ns ns
Interaction effect ns ns ns ns P = 0.0001 P = 0.0001 ns P = 0.0002 P = 0.04 ns ns ns ns ns ns ns ns

Cholesteryl esters are expressed as a percentage of the total CE of the LDL as determined by mass spectrometry. All values represent the means (± SEM) for 13–19 mice for each diet/genotype.

98% amino acid homology with mouse biglycan (30). As illustrated in Fig. 2A, each experiment consisted of a 700 s binding step as LDL isolated from pooled plasma samples from Soat2+/+ mice consuming the cis-MUFA diet (n = 3 mice/pool, 0–40 μg/ml LDL cholesterol) flowed over the immunoabsorbed BGN; this period was followed by a 1,000 s dissociation step as sample buffer was delivered to the chip. Each RU versus time trace has been corrected for nonspecific binding by subtracting the RU from the reference channel (which contained antibody alone) from the LDL binding signals from the sample channel that contained immunocaptured BGN. A comparison of data across experiments was facilitated by normalizing each peak and predissociation LDL RU value by the signal resulting from BGN immunocapture (RU). LDL binding at the peak responses are plotted as a function of LDL cholesterol concentration and fitted to a one-site binding model for particles isolated from pooled plasma from each experimental group shown in Fig. 2B. Using SigmaPlot 11.0, the Kd and Bmax were calculated for all experimental groups, and the values represent LDL from the Soat2+/+ mice consuming the cis-MUFA diet and the average of the LDL from the remaining three experimental groups, inasmuch as the curves for the latter were essentially superimposable. LDL cholesterol (23.3 μg/ml) was required from the Soat2+/+ group consuming the cis-MUFA diet to bind to half the proteoglycan sites at equilibrium (Kd). In comparison, the other three experimental groups required 3-fold higher concentrations of LDL cholesterol (68 μg/ml) to achieve the same amount of binding. Additionally, Bmax, the ratio of LDL binding RU to BGN-captured RU for the LDL from the Soat2+/+ mice consuming the cis-MUFA diet, was also higher compared with the other experimental groups (1.66 versus 1.35).

LDL binding to BGN was also measured using LDL particles isolated from plasma of individual mice at a concentration of 30 μg/ml of LDL cholesterol. LDL of Soat2+/+ mice consuming the cis-MUFA diet had the highest affinity to BGN, as illustrated by the prompt, large signal changes (RU) presented in Fig. 3A, top trace. LDL particles isolated from individual Soat2+/+ mice consuming the n-3 PUFA diet exhibited about a 2-fold reduction in binding affinity in this experiment. Even greater signal reductions were observed with LDL particles isolated from Soat2−/− mice fed the cis-MUFA and the n-3 PUFA diets, as illustrated by the kinetic traces shown in Fig. 3A. Incubating LDL particles with excess chondroitin sulfate (CS) GAGs to block potential binding sites reduced the RU signals essentially to baseline (Fig. 3A, bottom trace), confirming the specificity of LDL:BGN binding.

LDL from all experimental mice resulted in a rapid rise in RU during the initial ~300 s of the binding phase.
delivery continued out to 700 s. For example, the ratio of the peak to predissociation RU signals averaged $1.34 \pm 0.14$ (n = 6) for LDL particles from $Soat2^{+/-}$ mice consuming the $cis$-MUFA diet. Buffer delivery reduced the RU signals even more.

Kinetic analyses for the various study groups yielded comparable although sometimes variable half-times that were not apparently related to the relative RU response. Peak RU signals were typically followed by a small drop in RU as LDL

---

**Fig. 3.** Interaction of LDL isolated from plasma of individual apoB-100-only $Ldlr^{-/-}$ mice with immobilized biglycan as assessed by SPR. Binding was determined using 30 µg/ml of LDLc isolated from plasma of individual mice. A: Representative kinetic plots of LDL binding for a representative mouse LDL sample from each experimental group. CS shows chondroitin sulfate inhibition of LDL binding where LDL from a $Soat2^{+/-}$ mouse consuming the $cis$-MUFA diet was studied. B: Peak binding responses of LDL particles. The bars represent the means (± SEM) for 6–12 mice for each diet/genotype group; for all groups of mice, diet was fed for 12 weeks at the time of blood sampling. By two-way ANOVA, the diet effect was significant ($P = 0.0006$), and the responses for $Soat2^{+/-}$ versus $Soat2^{-/-}$ groups were significantly different ($P = 0.005$), but there was no significant interaction. C: Binding of LDL particles isolated from $Soat2^{+/-}$ mice consuming the $cis$-MUFA diet incubated with or without 25 µg/ml of CS GAGs. D: Regression analysis comparing LDL binding to immobilized BGN with the percentage of CO in the CE of the different LDL particles. The line is the least-squares best-fit regression line, and the regression coefficient was highly significant.
further, to $0.48 \pm 0.18$ (n = 6) times the peak values for this group. The decreases in binding from the predissociation point during the buffer wash phase remained proportional for each experimental group. The reduction in RU signals may reflect the transient binding of metastable LDL aggregates that form and dissociate quickly from the immunocaptured biglycan. Alternatively, changes within the secondary structure of the biglycan may occur as a consequence of the LDL binding, limiting the available charged sequences. Interestingly, it has been reported that GAG chains present on proteoglycans can self-associate, and thus it is possible that after the initial interaction with LDL particles, the GAGs present on the biglycan may undergo a small conformational change. Such a change could not only result in the release of minor amounts of bound LDL particles but could also render previously accessible regions of the GAG chain inaccessible (31).

Results of the normalized peak analysis at the maximum response value for LDL of each combination of diet and genotype are presented as averaged data in bar graph format in Fig. 3B. Consistent with the data for LDL isolated from the pooled plasma (Fig. 2A), LDL particles isolated from individual Soat2+/− mice consuming the cis-MUFA diet had the highest affinity for BGN. Statistically significant differences in binding between diet and genotype groups were maintained when a similar analysis was applied to the predissociation binding signals (data not shown). Incubating LDL with CS successfully inhibited the LDL:BGN interaction with almost complete inhibition (>99%, n = 6) achieved by incubating with 25 μg/ml CS (Fig. 3C). Regression analysis was performed to investigate the relationship between the extent of LDL-biglycan binding and CE composition of LDL (Fig. 3D), and results revealed a highly significant positive association ($R^2 = 0.76$, $P < 0.0001$) between the percentage of CO in the LDL CE and the affinity of the LDL particle for BGN.

### Atherosclerosis

Finally, by quantifying the amount of CE deposited in the aorta during diet induction, the extent of atherosclerosis was evaluated in 21 individual LDL donor mice for which LDL BGN binding was also measured in terminal blood samples. Mice consuming dietary n-3 PUFA and mice with Soat2 gene deletions consistently had lower aortic CE levels compared with Soat2−/− mice consuming the cis-MUFA diet (Fig. 4A). Regression analysis was performed to investigate relationships between atherosclerosis extent and both the percentage of LDL CE as CO and LDL BGN binding (Fig. 4B, C). Results showed highly significant positive relationships between the extent of atherosclerosis and both the percentage of CE as CO in the core of the particle ($R^2 = 0.53$ $P = 0.0003$, Fig. 4B) and the LDL binding response to BGN ($R^2 = 0.49$ $P = 0.0008$, Fig. 4C).

### DISCUSSION

The principal finding of this study in a mouse model of atherosclerosis, the apoB-100-only Ldb−/− mouse, is that dietary changes and genetic manipulations that enrich the LDL particle core in CO promoted atherosclerosis and increased the affinity for LDL binding to the specific proteoglycan, biglycan, as quantified by a novel SPR method. Our approach provides real-time measurements of the rate and extent of formation and dissociation of LDL:BGN complexes, with a sensitivity comparable to solid-phase binding measurements that yield only affinity data (4). The primary compositional difference between LDL particles isolated from the Soat2−/− mice consuming the cis-MUFA diet and those from the other experimental groups is the abundance of monounsaturated CE packaged into the particle core. Regression analysis revealed strong and
highly significant correlations between the proportions of CE as CO in the LDL particle and the affinity for the immobile BGN. Additionally, there was a strong relationship between LDL binding and the degree of atherosclerosis that developed. These results indicate that SOAT2-derived CE containing monounsaturated FAs in the core of LDL may result in a prolonged residence time of LDL in the artery wall that could lead to accelerated development of atherosclerosis. These findings are in agreement with previous studies showing that dietary consumption of n-3 PUFAs by nonhuman primates resulted in the production of LDL particles with a decreased affinity for proteoglycans compared with their lard-fed counterparts (32–34).

This study also helps address a number of paradoxical questions that remain unanswered as to what factors appear to be more important in the development of atherosclerosis. Our report indicates that LDL particle composition is a critical factor driving atherogenesis. This becomes apparent when considering that there were no significant differences in plasma lipoprotein cholesterol concentrations between the Soat2+/+ and Soat2−/− mice consuming the cis-MUFA diet; in contrast, the Soat2−/− mice had significantly less CO in the particle core, which had been replaced with TG and CE containing n-6 polyunsaturated FAs, the latter presumably being derived from the plasma enzyme lecithin:cholesterol acyltransferase. At the same time, a large attenuation in the development of atherosclerosis was seen. This is an important observation when considering that monounsaturated fats such as olive oil are still being promoted as healthy and protective against heart disease (35–37). Additionally, several reports suggest that LDL particles enriched in polyunsaturated fats are more susceptible to oxidation (38, 39), a process thought to promote the development of atherosclerosis. Although this remains possible, our data demonstrate that packaging of the polyunsaturated FAs (n-3 or n-6) into the LDL core CE results in a reduced affinity of LDL particles for arterial proteoglycans. Thus, while being more susceptible to oxidation, such LDLs would probably have a shortened residence time in the artery wall, which may have the effect of limiting the oxidative modifications that can take place.

We used LDL isolated by gel filtration chromatography for the binding assays so that we did not modify the surface components, as might occur during ultracentrifugation. The LDL particles used in the binding assay were only in the narrow center cut from the LDL peak off the superose column. Necessarily, for compositional analyses, material from the entire column peak was analyzed, so it is possible that small differences in composition between the LDL used in the binding assay and the LDL analyzed for composition could have been present.

While a molecular mechanism directly responsible for the increased binding of CO-enriched LDL particles is not presented in this report, we postulate that the differences seen in this study are primarily a result of conformational differences in apoB-100 on the LDL particle surface. ApoB-100 contains several proteoglycan binding sites (40, 41), and the structure of apoB-100 on the LDL particle surface has been shown to be sensitive to both temperature and deviations in the organization of the neutral lipid core (42). The physical state of the LDL particle core is dependent upon fatty acyl composition, and it has been shown that the presence of more-saturated and monounsaturated FAs results in a more-liquid-crystalline (anisotropic) particle core, whereas a shift to more polyunsaturated FAs results in a more-liquid (isotropic) core. Thus, it seems reasonable that the LDL particles enriched with CE containing saturated and monounsaturated FAs would have an anisotropic core that could lead to a modified apoB-100 conformation where it extends farther outside of the PL monolayer (43), for example. We speculate that this could result in an LDL particle with more proteoglycan binding sites exposed on the particle surface, which act cooperatively to increase interactions with proteoglycans. The consequent result could be increased LDL retention in the arterial intima and more atherosclerosis.

The authors thank Dr. Rick Owens (LifeCell Corporation, Branchburg, NJ) for providing the recombinant human biglycan used in this study. We acknowledge the mass spectrometry core lab run by Dr. Michael Thomas and Mike Samuels (Wake Forest School of Medicine, Biochemistry Department) for performing the mass spectrometry analyses on the LDL particle cholesterol esters. Thanks to Mary C. Stahle for her expert technical assistance with the SPR measurements.

REFERENCES

1. Roger, V. L., A. S. Go, D. M. Lloyd-Jones, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, et al. 2012. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 125:e180–e223.

2. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 551–561.

3. Camejo, G. 1982. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherosclerosis. Adv. Lipid Res. 19: 1–53.

4. Skålén, K., M. Gustafsson, E. K. Rydberg, L. M. Hulten, O. Wiklund, T. L. Innerarity, and J. Boren. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417: 750–754.

5. O’Brien, K. D., K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait. 1998. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 98: 519–527.

6. Zeng, X., J. Chen, Y. I. Miller, K. Javaherian, and K. S. Moulton. 2005. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J. Lipid Res. 46: 1849–1859.

7. Kunjathoor, V. V., D. S. Chiu, K. D. O’Brien, and R. C. LeBoeuf. 2002. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 462–468.

8. Bell III, T. A., K. Kelley, M. D. Wilson, J. K. Sawyer, and L. L. Rudel. 2007. Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr−/− mice. Arterioscler. Thromb. Vasc. Biol. 27: 1396–1402.

9. Rudel, L. L., M. G. Bond, and B. C. Bullock. 1985. LDL heterogeneity and atherosclerosis in nonhuman primates. Ann. N. Y. Acad. Sci. 454: 248–253.

10. Rudel, L. L., F. L. Johnson, J. K. Sawyer, M. S. Wilson, and J. S. Parks. 1995. Dietary polyunsaturated fat modifies low-density lipoproteins and reduces atherosclerosis of nonhuman primates with high and low diet responsiveness. Am. J. Clin. Nutr. 62: 463S–470S.
Cholesteryl oleate increases LDL-biglycan binding